Pharmacogenetics in the clinic

por Guchelaar, H.-J.
Publicado 2013

Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands

por Bank, P. C. D., Swen, J. J., Guchelaar, H. J.
Publicado 2019

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease

por Krens, L. L., Baas, J. M., Guchelaar, H. J., Gelderblom, H.
Publicado 2017

Regarding: ‘Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array’

por Pander, J, Gelderblom, H, van der Straaten, T, Punt, C J A, Guchelaar, H-J
Publicado 2010

UGT1A1(*)28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study

por Kweekel, D M, Gelderblom, H, Van der Straaten, T, Antonini, N F, Punt, C J A, Guchelaar, H-J
Publicado 2008

Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.

por Guchelaar, H. J., Hoekstra, H. J., de Vries, E. G., Uges, D. R., Oosterhuis, J. W., Schraffordt Koops, H.
Publicado 1992

Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array

por Kweekel, D M, Antonini, N F, Nortier, J W R, Punt, C J A, Gelderblom, H, Guchelaar, H-J
Publicado 2009

CYP2D6 Metabolism in Frail Elderly Compared to Non-Frail Elderly: A Pilot Feasibility Study

por Opdam, F. L., Modak, A. S., Mooijaart, S. P., Louwerens, M., de Waal, M. W. M., Gelderblom, H., Guchelaar, H.-J.
Publicado 2015

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism

por Sanchez Spitman, A. B., Moes, D. J. A. R., Gelderblom, H., Dezentje, V. O., Swen, J.J., Guchelaar, H. J.
Publicado 2017

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse

por Sanchez-Spitman, A. B., Swen, J. J., Dezentjé, V. O., Moes, D. J. A. R., Gelderblom, H., Guchelaar, H. J.
Publicado 2021

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients

por Baas, J. M., Krens, L. L., ten Tije, A. J., Erdkamp, F., van Wezel, T., Morreau, H., Gelderblom, H., Guchelaar, H. J.
Publicado 2015

Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers

por van Rongen, A, Kervezee, L, Brill, MJE, van Meir, H, den Hartigh, J, Guchelaar, H-J, Meijer, JH, Burggraaf, J, van Oosterhout, F
Publicado 2015

GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group

por Kweekel, D M, Koopman, M, Antonini, N F, Van der Straaten, T, Nortier, J W R, Gelderblom, H, Punt, C J A, Guchelaar, H-J
Publicado 2008

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19

por Swen, J. J., van der Straaten, T., Wessels, J. A. M., Bouvy, M. L., Vlassak, E. E. W., Assendelft, W. J. J., Guchelaar, H.-J.
Publicado 2011

Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation

por van der Stoep, M. Y. E. C., Zwaveling, J., Bertaina, A., Locatelli, F., Guchelaar, H. J., Lankester, A. C., Moes, D. J. A. R.
Publicado 2019

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer

por Souwer, E. T. D., Sanchez-Spitman, A., Moes, D. J. A. R., Gelderblom, H., Swen, J. J., Portielje, J. E. A., Guchelaar, H. J., van Gelder, T.
Publicado 2023

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

por Gietema, J. A., de Vries, E. G., Sleijfer, D. T., Willemse, P. H., Guchelaar, H. J., Uges, D. R., Aulenbacher, P., Voegeli, R., Mulder, N. H.
Publicado 1993

Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands

por van Laar, S.A., Gombert-Handoko, K.B., Groenwold, R.H.H., van der Hulle, T., Visser, L.E., Houtsma, D., Guchelaar, H.J., Zwaveling, J.
Publicado 2022

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.

por Gietema, J. A., Veldhuis, G. J., Guchelaar, H. J., Willemse, P. H., Uges, D. R., Cats, A., Boonstra, H., van der Graaf, W. T., Sleijfer, D. T., de Vries, E. G.
Publicado 1995

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

por Schneider, T. C., de Wit, D., Links, T. P., van Erp, N. P., van der Hoeven, J. J. M., Gelderblom, H., van Wezel, T., van Eijk, R., Morreau, H., Guchelaar, H. J., Kapiteijn, E.
Publicado 2015